Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients
Autore:
Novotny, J; Petruzelka, L; Vedralova, J; Kleibl, Z; Matous, B; Judas, L;
Indirizzi:
Charles Univ, Fac Med 1, Dept Oncol, Prague 12808, Czech Republic Charles Univ Prague Czech Republic 12808 l, Prague 12808, Czech Republic Gen Teaching Hosp, Prague 12808, Czech Republic Gen Teaching Hosp PragueCzech Republic 12808 ague 12808, Czech Republic Charles Univ, Fac Med 1, Hlavas Dept Pathol, Prague 12808, Czech Republic Charles Univ Prague Czech Republic 12808 l, Prague 12808, Czech Republic Charles Univ, Fac Med 1, Dept Med Chem & Biochem, Prague 12808, Czech Republic Charles Univ Prague Czech Republic 12808 m, Prague 12808, Czech Republic
Titolo Testata:
NEOPLASMA
fascicolo: 3, volume: 48, anno: 2001,
pagine: 188 - 191
SICI:
0028-2685(2001)48:3<188:PSOCGE>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
HER-2/NEU EXPRESSION; ADENOCARCINOMA; OVEREXPRESSION; SURVIVAL; ONCOGENE; P53;
Keywords:
c-erbB-2; HER2/neu; pancreatic cancer; carcinoid; insulinoma; prognostic factor;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
18
Recensione:
Indirizzi per estratti:
Indirizzo: Novotny, J Charles Univ, Fac Med 1, Dept Oncol, Prague 12808, Czech Republic Charles Univ Prague Czech Republic 12808 2808, Czech Republic
Citazione:
J. Novotny et al., "Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients", NEOPLASMA, 48(3), 2001, pp. 188-191

Abstract

Molecular methods tend to belong to the standard armamentarium of modem pathology. In some instances, these methods are able to identify nosological entities with better accuracy than conventional technique. These methods give useful complementary information to choose appropriate therapeutic strategy. C-erbB-2 overexpression in pancreatic cancer vary widely between 17 to82%. C-erbB-2 gene is perspective target of anticancer therapies.57 histologically confirmed tumors (51 pancreatic adenocarcinoma, 5 pancreatic neuroendocrine tumors and 1 carcinoma of Vater's ampullae) were analyzed for the presence of c-erbB-2 expression by immunohistochemistry. Correlation with time from initial symptoms until diagnosis, tumor size and TNM stage at diagnosis, tumor grade, type of operation and overall survival were investigated. C-erbB-2 overexpression was detected in 19.6% samples of pancreatic adenocarcinoma and in one case of Vater's ampullae carcinoma. C-erbB-2 overexpression was found in two of four insulinomas. Univariate statistical correlation between c-erbB-2 overexpression and time from initial symptoms until diagnosis, tumor size and TNM stage at diagnosis, tumor grade, type of operation and overall survival did not reach statistical significans in any parameter studied. C-erbB-2 oncogene was not found to be prognostic factor in pancreatic cancer. Its value to predict therapeutical response remains to be determined inprospective clinical trials.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 10:15:11